These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24969005)

  • 1. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving provider payment models and patient access to innovative medical technology.
    Long G; Mortimer R; Sanzenbacher G
    J Med Econ; 2014 Dec; 17(12):883-93. PubMed ID: 25221929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-part payments for the reimbursement of investments in health technologies.
    Levaggi R; Moretto M; Pertile P
    Health Policy; 2014 Apr; 115(2-3):230-6. PubMed ID: 24268054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
    Hammerman A; Feder-Bubis P; Greenberg D
    Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
    Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
    Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Funding technology: evaluating and exercising the leasing option.
    McIntire M; Waldron DJ
    Healthc Financ Manage; 2006 Nov; 60(11):92-8, 100. PubMed ID: 17094283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of technology on health care cost and policy development.
    Wallner PE; Konski A
    Semin Radiat Oncol; 2008 Jul; 18(3):194-200. PubMed ID: 18513629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making the right long-term prescription for medical equipment financing.
    Conbeer GP
    Healthc Financ Manage; 2007 Jun; 61(6):88-93. PubMed ID: 17571713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Innovative patient access schemes for the adoption of new technology: risk-sharing agreements].
    Espín J; Oliva J; Rodríguez-Barrios JM
    Gac Sanit; 2010; 24(6):491-7. PubMed ID: 21074292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
    Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
    Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Financing problems of capital goods: part 1: leasing as a solution?].
    Clausen CC; Bauer M; Saleh A; Picker O
    Anaesthesist; 2008 Jun; 57(6):607-12. PubMed ID: 18516573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of reimbursement mechanisms on medical technology diffusion in the hospital sector in the Italian NHS.
    Finocchiaro Castro M; Guccio C; Pignataro G; Rizzo I
    Health Policy; 2014 Apr; 115(2-3):215-29. PubMed ID: 24393709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.